Corporate Breaking News
Corporate Breaking News
Home : Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO
May 14
2020

Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO

OSLO, Norway, May 14, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that an abstract relating to the dose escalation part of the ONCOS-102 and durvalumab trial in...
Source:https://www.prnewswire.com:443/news-releases/targovax-announces-that-the-oncos-102-and-durvalumab-abstract-is-selected-for-a-poster-discussion-session-at-asco-301059127.html
 
Related News
» Polyplastics lança nova grade de POM DURACON(R) com resistência melhorada a combustível diesel para componentes de combustível automotivo
» 2Africa: a transformative subsea cable for future internet connectivity in Africa announced by global and African partners
Home
About us
Archive
Sitemap
Powered By Corporate Breaking News.com Home| About us| Archive News| Sitemap